Enzon Pharmaceuticals, Inc.

of this Current Report, which are hereby incorporated herein by reference. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. C

. The issuance of such shares of Company Common Stock was made in reliance upon the exemption contained in Section 4(a)(2) of the Securities Act of 1933, as ame

Changes in Control of the Registrant. The disclosure under Item 2.01 in this Current Report on Form 8-K is incorporated herein by reference under this Item 5.01

of this Current Report, reference is made to the disclosure described in the Prospectus/Consent Solicitation/Offer to Exchange in the section entitled “Director

Regulation FD Disclosure. On March 26, 2026, the Company issued a press release announcing the completion of the Merger. A copy of the press release is attached

(b) of Form 8-K will be filed by amendment within 71 calendar days after the date on which this Current Report on Form 8-K is required to be filed. (d) Exhibits